RADX vs RNW

For growth investors, Radiopharm Theranostics Limited (RADX) is the stronger pick with 1114% revenue growth year-over-year, versus 19.

4% for ReNew Energy Global Plc (RNW). ReNew Energy Global Plc (RNW) offers the better valuation at 46. 9x trailing P/E (0. 4x forward), making it the more compelling value choice. Analysts rate ReNew Energy Global Plc (RNW) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ReNew Energy Global Plc (RNW) delivered a total return of -45.

7%, compared to -76. 5% for Radiopharm Theranostics Limited (RADX). Over 10 years, the gap is even starker: RNW returned -50. 5% versus RADX's -76. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ReNew Energy Global Plc (RNW) is the lower-risk stock at 0.

62β versus Radiopharm Theranostics Limited's 0. 88β — meaning RADX is approximately 41% more volatile than RNW relative to the S&P 500.

By revenue growth (latest reported year), Radiopharm Theranostics Limited (RADX) is pulling ahead at 1114% versus 19.

4% for ReNew Energy Global Plc (RNW). On earnings-per-share growth, the picture is similar: Radiopharm Theranostics Limited grew EPS 85. 3% year-over-year, compared to 10. 1% for ReNew Energy Global Plc. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ReNew Energy Global Plc (RNW) is the more profitable company, earning 3.

9% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 3. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ReNew Energy Global Plc (RNW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

62)). Both have compounded well over 10 years (RNW: -50. 5%, RADX: -76. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RADX (Healthcare) and RNW (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.